
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…
Founded: 2023
Headquarters: Villejuif, Île-de-France, France
Focus: AI-powered precision oncology platform for drug development
Flagship products: O-Predict; O-Validate
Notable funding: Seed round (Dec 2024); ~€11M–€15M total raised
28 employees
Cancer drug development, with an emphasis on colorectal and pancreatic cancers
2023
Biotechnology Research
≈€11,000,000
Seed round announced Dec 3, 2024; reporting cites nondilutive support from Bpifrance and total capital raised to date near €15M in some sources.
“Bpifrance; Singular; additional investors recorded (Amazon Web Services, HCVC, SistaFund, Speedinvest, Verve Ventures)”
At Orakl Oncology, we are accelerating the development of oncology treatments. Today, fewer than 5% of new cancer drugs succeed in clinical trials. Clearly, new methods are needed. We combine cutting-edge biology and AI to build the next generation of insight platforms with the world’s largest cohort of patient tumor avatars. These avatars fuel our AI-powered predictive engine, helping to anticipate clinical trial outcomes, validate therapies, and uncover new drug candidates. By generating multimodal, real-world data, we deliver insights that consistently outperform existing solutions.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,500+
New This Week
| Company |
|---|
Our mission is simple yet ambitious: to bring more effective treatments to patients who need them — and to make drug development smarter, faster, and more personalized. We collaborate with top hospitals, research institutes, and pharmaceutical companies worldwide. Backed by leading investors, we are a fast-growing, mission-driven startup at the intersection of science and technology.### Position overview
We have built a unique dataset that combines omics data with functional readouts from our patient-derived organoid (PDO) avatars platform, enabling us to identify novel biomarkers and therapeutic targets. To unlock the full potential of this data at scale, we are looking for a Research Engineer to lead the productionization, continuous integration, and maintenance of the computational pipelines that power this work. The challenge is concrete: what reliable signal can we extract when we cross molecular profiles with drug response data and how fast can we turn that into production-grade methods that teams use every day? The methods you build will become the backbone of Orakl’s omics analysis codebase. You will work from features already extracted from production omics pipelines, design methods that extract actionable signals, and ship them as robust, automated pipelines the entire company relies on.
At Orakl Oncology, we are generating a unique and novel dataset, thanks to which we advance the fight against cancer. As a Research Engineer, the code you write will be used every day by teams across the company to generate actionable insights from real patient-derived data.
Your contributions will be critical and highly visible. The results your work will produce will directly influence key drug development decisions. This role is perfect for a candidate that wants to work on complex biological data, write clean code and have an outsized impact on the fight against cancer.HR Call (20 minutes call) – An initial discussion to better understand your background, experiences, and motivations.
Technical Interview (45 minutes call) – A deep dive into your technical skills and expertise relevant to the role.
Technical Case (1 hour presentation + discussion) - A case study or problem-solving exercise to assess your strategic thinking and analytical abilities. If possible this can be done in person.
Founders Culture Interview (45 minutes)- As final step of our recruitment process, you will meet the founders of Orakl Oncology in person at our office. This meeting is an opportunity for the founders to assess cultural fit and ensure alignment with our company values.